• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃肠道癌症中的基因与自分泌运动因子-溶血磷脂酸轴

gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.

作者信息

Wang Shuo, Chen Jiang, Guo Xiao-Zhong

机构信息

Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China.

出版信息

World J Gastrointest Oncol. 2022 Aug 15;14(8):1388-1405. doi: 10.4251/wjgo.v14.i8.1388.

DOI:10.4251/wjgo.v14.i8.1388
PMID:36160748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9412925/
Abstract

The gene inhibits the metastasis of most tumors and is remarkably correlated with tumor invasion and prognosis. Cell metabolism dysregulation is an important cause of tumor occurrence, development, and metastasis. As one of the important characteristics of tumors, cell metabolism dysregulation is attracting increasing research attention. Phospholipids are an indispensable substance in the metabolism in various tumor cells. Phospholipid metabolites have become important cell signaling molecules. The pathological role of lysophosphatidic acid (LPA) in tumors was identified in the early 1990s. Currently, LPA inhibitors have entered clinical trials but are not yet used in clinical treatment. Autotaxin (ATX) has lysophospholipase D (lysoPLD) activity and can regulate LPA levels . The LPA receptor family and ATX/lysoPLD are abnormally expressed in various gastrointestinal tumors. According to our recent pre-experimental results, KAI1/CD82 might inhibit the migration and metastasis of cancer cells by regulating the ATX-LPA axis. However, no relevant research has been reported. Clarifying the mechanism of ATX-LPA in the inhibition of cancer metastasis by KAI1/CD82 will provide an important theoretical basis for targeted cancer therapy. In this paper, the molecular compositions of the gene and the ATX-LPA axis, their physiological functions in tumors, and their roles in gastrointestinal cancers and target therapy are reviewed.

摘要

该基因可抑制大多数肿瘤的转移,且与肿瘤侵袭和预后显著相关。细胞代谢失调是肿瘤发生、发展和转移的重要原因。作为肿瘤的重要特征之一,细胞代谢失调正吸引着越来越多的研究关注。磷脂是各种肿瘤细胞代谢中不可或缺的物质。磷脂代谢产物已成为重要的细胞信号分子。溶血磷脂酸(LPA)在肿瘤中的病理作用于20世纪90年代初被发现。目前,LPA抑制剂已进入临床试验阶段,但尚未用于临床治疗。自分泌运动因子(ATX)具有溶血磷脂酶D(lysoPLD)活性,可调节LPA水平。LPA受体家族以及ATX/lysoPLD在各种胃肠道肿瘤中均有异常表达。根据我们最近的实验前结果,KAI1/CD82可能通过调节ATX-LPA轴来抑制癌细胞的迁移和转移。然而,尚未有相关研究报道。阐明ATX-LPA在KAI1/CD82抑制癌症转移中的机制,将为癌症靶向治疗提供重要的理论基础。本文对该基因和ATX-LPA轴的分子组成、它们在肿瘤中的生理功能以及它们在胃肠道癌症和靶向治疗中的作用进行了综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dcb/9412925/745afed00af1/WJGO-14-1388-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dcb/9412925/745afed00af1/WJGO-14-1388-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dcb/9412925/745afed00af1/WJGO-14-1388-g001.jpg

相似文献

1
gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.胃肠道癌症中的基因与自分泌运动因子-溶血磷脂酸轴
World J Gastrointest Oncol. 2022 Aug 15;14(8):1388-1405. doi: 10.4251/wjgo.v14.i8.1388.
2
Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer.自分泌运动因子/自分泌运动因子-溶血磷脂酸轴在肝癌发生发展中的作用
Front Oncol. 2022 Jun 13;12:922945. doi: 10.3389/fonc.2022.922945. eCollection 2022.
3
New insights into the autotaxin/LPA axis in cancer development and metastasis.对自分泌运动因子/溶血磷脂酸轴在癌症发生和转移中的新见解。
Exp Cell Res. 2015 May 1;333(2):183-189. doi: 10.1016/j.yexcr.2014.11.010. Epub 2014 Nov 25.
4
Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD).黏膜下结缔组织型肥大细胞通过自分泌运动因子(ATX)/溶血磷脂酶D(lysoPLD)的分泌,促进胃肠道中溶血磷脂酸(LPA)的产生。
Virchows Arch. 2007 Jul;451(1):47-56. doi: 10.1007/s00428-007-0425-4. Epub 2007 Jun 7.
5
Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD Cell Line.基于 PANC1-KAI1/CD 细胞系构建的胰腺癌和肝转移裸鼠模型的代谢组学检测。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045204. doi: 10.1177/15330338211045204.
6
Design and Development of Autotaxin Inhibitors.自分泌运动因子抑制剂的设计与开发
Pharmaceuticals (Basel). 2021 Nov 22;14(11):1203. doi: 10.3390/ph14111203.
7
Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.自分泌运动因子在癌症转移和自身免疫性疾病中的作用:自分泌运动因子与细胞表面结合的功能意义
Cancers (Basel). 2019 Dec 31;12(1):105. doi: 10.3390/cancers12010105.
8
Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.自分泌运动因子-溶血磷脂酸受体轴对肿瘤细胞-微环境相互作用的调控
Adv Biol Regul. 2019 Jan;71:183-193. doi: 10.1016/j.jbior.2018.09.008. Epub 2018 Sep 16.
9
Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.自主分泌酶/溶血磷脂酸轴:从骨生物学到骨疾病。
Int J Mol Sci. 2022 Mar 22;23(7):3427. doi: 10.3390/ijms23073427.
10
CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1.CD82/KAI1 通过 TGF-β1 抑制食管鳞癌细胞的侵袭和转移。
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5928-5937. doi: 10.26355/eurrev_201809_15922.

引用本文的文献

1
Lipid Metabolism in Gastrointestinal Malignancies: Exploring Dysregulation, Biomarkers, and Treatment Strategies.胃肠道恶性肿瘤中的脂质代谢:探索失调、生物标志物和治疗策略
Cancer Med. 2025 May;14(10):e70975. doi: 10.1002/cam4.70975.
2
EccDNA-Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation.环状染色体外DNA驱动的VPS41扩增通过溶酶体KAI1降解减轻基因毒性应激
Adv Sci (Weinh). 2025 Jul;12(25):e2501934. doi: 10.1002/advs.202501934. Epub 2025 Apr 24.
3
The Emerging Role of LPA as an Oncometabolite.LPA 作为一种致癌代谢物的新兴作用。

本文引用的文献

1
LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.LPA3 是卵巢癌的精确治疗靶点和潜在生物标志物。
Med Oncol. 2022 Jan 4;39(2):17. doi: 10.1007/s12032-021-01616-5.
2
LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.LPAR5 通过激活 class IA PI3K 催化亚基 p110β 促进甲状腺癌细胞增殖和迁移。
Cancer Sci. 2021 Apr;112(4):1624-1632. doi: 10.1111/cas.14837. Epub 2021 Mar 6.
3
Different effects of lysophosphatidic acid receptor-2 (LPA) and LPA on the regulation of chemoresistance in colon cancer cells.
Cells. 2024 Apr 4;13(7):629. doi: 10.3390/cells13070629.
溶血磷脂酸受体-2(LPA)和溶血磷脂酸对结肠癌细胞化疗耐药性调节的不同作用。
J Recept Signal Transduct Res. 2021 Feb;41(1):93-98. doi: 10.1080/10799893.2020.1794002. Epub 2020 Jul 16.
4
Regulation of Tumor Immunity by Lysophosphatidic Acid.溶血磷脂酸对肿瘤免疫的调节作用
Cancers (Basel). 2020 May 10;12(5):1202. doi: 10.3390/cancers12051202.
5
A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells.肝癌细胞中溶血磷脂酸受体 6(LPAR6)表达诱导的特征性蛋白谱。
Biochem Biophys Res Commun. 2020 Jun 11;526(4):1150-1156. doi: 10.1016/j.bbrc.2020.04.036. Epub 2020 Apr 19.
6
Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy.自分泌酶-溶血磷脂酸轴在癌症治疗耐药性发展中的作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Aug;1865(8):158716. doi: 10.1016/j.bbalip.2020.158716. Epub 2020 Apr 16.
7
Lysophosphatidic acid receptor-2 (LPA)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs.溶血磷脂酸受体-2(LPA)介导的信号通路增强了接受抗癌药物治疗的黑色素瘤细胞的耐药性。
Mol Cell Biochem. 2020 Jun;469(1-2):89-95. doi: 10.1007/s11010-020-03730-w. Epub 2020 Apr 16.
8
Correlation of KAI1, CD133 and vasculogenic mimicry with the prediction of metastasis and prognosis in hepatocellular carcinoma.KAI1、CD133与血管生成拟态在肝细胞癌转移及预后预测中的相关性
Int J Clin Exp Pathol. 2018 Jul 1;11(7):3638-3646. eCollection 2018.
9
A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.肝癌治疗的一个潜在靶点,溶血磷脂酸受体 6(LPAR6),其转录受到 NCOA3 共激活因子的上调。
J Biol Chem. 2020 Feb 7;295(6):1474-1488. doi: 10.1074/jbc.RA119.009899. Epub 2019 Dec 30.
10
LPA receptor1 antagonists as anticancer agents suppress human lung tumours.LPA 受体 1 拮抗剂作为抗癌药物抑制人肺癌肿瘤。
Eur J Pharmacol. 2020 Feb 5;868:172886. doi: 10.1016/j.ejphar.2019.172886. Epub 2019 Dec 19.